Sarcomas

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Sarcomas is an early-stage landscape with 0 programs across 1 company. The most active players are Ratio Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Ratio Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed3 · 50%

Recruiting2 · 33%

Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT07014137·20 enrolled

Actinium Therapy for Late-stage Aggressive Sarcomas

Recruiting·RRatio Therapeutics, Inc.·Phase 1·NCT07156565·30 enrolled

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

Completed·AAEterna Zentaris·Phase 2·NCT00401388·72 enrolled

Thalidomide in Treating Patients With Gynecologic Sarcomas

Completed·—·Phase 2·NCT00006005

Validation of a Genetic Signature to Predict the Development of Sarcomas

Completed·CCentre Georges Francois Leclerc·N/A·NCT03625791·60 enrolled

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Withdrawn·—·N/A·NCT01663090

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)